GSA Capital Partners LLP Sells 5,529 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)

GSA Capital Partners LLP lowered its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 13.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,402 shares of the company’s stock after selling 5,529 shares during the quarter. GSA Capital Partners LLP’s holdings in Inozyme Pharma were worth $185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Inozyme Pharma by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,427 shares of the company’s stock valued at $96,000 after buying an additional 2,690 shares in the last quarter. American Century Companies Inc. lifted its position in Inozyme Pharma by 11.0% during the second quarter. American Century Companies Inc. now owns 57,100 shares of the company’s stock valued at $255,000 after acquiring an additional 5,673 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in Inozyme Pharma in the second quarter valued at approximately $52,000. Rhumbline Advisers grew its holdings in Inozyme Pharma by 22.0% in the second quarter. Rhumbline Advisers now owns 77,004 shares of the company’s stock worth $343,000 after purchasing an additional 13,867 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Inozyme Pharma by 8.1% during the second quarter. Renaissance Technologies LLC now owns 187,839 shares of the company’s stock worth $838,000 after purchasing an additional 14,139 shares in the last quarter. 88.30% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on INZY shares. Stifel Nicolaus began coverage on Inozyme Pharma in a research report on Thursday, September 12th. They issued a “buy” rating and a $16.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $14.00 price target on shares of Inozyme Pharma in a report on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a report on Wednesday, November 6th. Wedbush reaffirmed an “outperform” rating and issued a $12.00 price objective (down from $15.00) on shares of Inozyme Pharma in a research report on Tuesday, November 5th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $17.00 target price (up previously from $16.00) on shares of Inozyme Pharma in a research report on Tuesday, August 13th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $15.71.

Inozyme Pharma Trading Up 4.5 %

Shares of Inozyme Pharma stock opened at $2.81 on Monday. The stock has a market cap of $180.51 million, a PE ratio of -1.80 and a beta of 1.54. The firm has a fifty day moving average price of $4.66 and a 200 day moving average price of $4.83. Inozyme Pharma, Inc. has a 1 year low of $2.61 and a 1 year high of $7.80. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68.

Inozyme Pharma (NASDAQ:INZY) last issued its earnings results on Tuesday, November 5th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. Equities research analysts predict that Inozyme Pharma, Inc. will post -1.59 earnings per share for the current year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.